Molecular Formula | C26H43BrO9 |
Molar Mass | 579.53 |
Density | 1.22±0.1 g/cm3(Predicted) |
Melting Point | 147-148°C |
Boling Point | 530.5±50.0 °C(Predicted) |
Flash Point | 274.6°C |
Solubility | Chloroform (Sparingly) |
Vapor Presure | 2.45E-11mmHg at 25°C |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | Inert atmosphere,2-8°C |
Stability | Light Sensitive, Moisture Sensitive |
Refractive Index | 1.494 |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. |
introduction | 2,3,4,6-O-tetra-pentanyl-alpha-D-bromo-glucopyranose can be used to prepare canagliflozin. Canaglifloin Canagliflozin is the first SGLT2 inhibitor drug approved by FDA. It can reduce blood sugar by decomposing glucose and excreting it through the kidneys. It has broad prospects for the treatment of adult type 2 diabetes. |
preparation method | using ALPHA-D-glucose as raw material, after reacting with tervaloyl chloride to protect all hydroxyl groups, then reacting with zinc bromide and trimethylbromosilane at -10 ℃ to form intermediate 4, and adding a small amount of thionyl chloride to the process of protecting group, so that the dosage of tervaloyl chloride is reduced by half, and the yield is not affected, the two-step yield is above 82%, and the total yield is more than 67%. |